Journal
ONCOIMMUNOLOGY
Volume 8, Issue 6, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2019.1581531
Keywords
Fusobacterium nucleatum; CEACAM1; inhibition of killing
Categories
Funding
- Israel Cancer Research Fund Project
- Israel Science Foundation [201/15]
- Israel-China Science Foundation
- GIF foundation
- ICRF professorship grant
- Helmholtz Israel grant
- Marry Curie grant
- ISF Moked grant
- Ministry of Science and Technology
Ask authors/readers for more resources
Fusobacterium nucleatum (F. nucleatum) is an oral anaerobe found to be enriched in colorectal cancer (CRC). Presence of F. nucleatum in CRC has been correlated with resistance to chemotherapy and poor prognosis. We previously demonstrated that the Fap2 outer-surface protein of F. nucleatum binds and activates the human inhibitory receptor TIGIT which is expressed by T and Natural Killer (NK) cells, and inhibits anti-tumor immunity. Here we show that F. nucleatum also binds and activates the human inhibitory receptor CEACAM1 leading to inhibition of T and NK cells activities. Our results suggest that using CEACAM1 and TIGIT inhibitors and specific targeting of fusobacteria should be considered for treating fusobacteria-colonized tumors
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available